Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin

被引:9
|
作者
Watanabe, Daichi [1 ]
Fujii, Hironori [1 ]
Yamada, Yunami [1 ]
Iihara, Hirotoshi [1 ]
Ishihara, Takuma [2 ]
Matsuhashi, Nobuhisa [3 ]
Takahashi, Takao [3 ]
Yoshida, Kazuhiro [3 ]
Suzuki, Akio [1 ]
机构
[1] Gifu Univ Hosp, Dept Pharm, Yanagido 1-1, Gifu 5011194, Japan
[2] Gifu Univ, Gifu Univ Hosp, Innovat & Clin Res Promot Ctr, Gifu, Japan
[3] Gifu Univ, Dept Surg Oncol, Grad Sch Med, Gifu, Japan
关键词
Oxaliplatin; creatinine clearance; adverse events; colorectal cancer; nausea; CAPECITABINE PLUS OXALIPLATIN; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; ADJUVANT TREATMENT; FLUOROURACIL; LEUCOVORIN; PHARMACOKINETICS; THERAPY; CHEMOTHERAPY;
D O I
10.21873/anticanres.13953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To clarify whether renal dysfunction affects the incidence of adverse events associated with oxaliplatin, the present study was designed to investigate the relationship between creatinine clearance (Ccr) and the incidence of oxaliplatin-related adverse events. Patients and Methods: A total of 287 CRC patients who received the first cycle of oxaliplatin-based chemotherapy were eligible. Adverse events, including nausea, vomiting, neutropenia and thrombocytopenia, were graded, and the relationship between Ccr and the incidence of adverse events was examined using multivariable logistic regression analysis. Results: A multivariable analysis indicated that the incidence of grade >= 2 nausea increased, while the incidence of other adverse events tended to be higher, as the Ccr decreased. Particularly, renal dysfunction (Ccr <60 ml/min) was a significant risk factor for grade >= 2 nausea (p=0.042). Conclusion: Care should be taken to avoid adverse events associated with oxaliplatin in patients with renal dysfunction.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [41] Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    Tebbutt, N. C.
    Murphy, F.
    Zannino, D.
    Wilson, K.
    Cummins, M. M.
    Abdi, E.
    Strickland, A. H.
    Lowenthal, R. M.
    Marx, G.
    Karapetis, C.
    Shannon, J.
    Goldstein, D.
    Nayagam, S. S.
    Blum, R.
    Chantrill, L.
    Simes, R. J.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1834 - 1838
  • [42] Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice
    Sukel, Myrthe P. P.
    Breekveldt-Postma, Nancy S.
    Erkens, Joelle A.
    van der Linden, Paul D.
    Beiderbeck, Annette B.
    Coebergh, Jan Willem W.
    Herings, Ron M. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (02) : 125 - 134
  • [43] Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients
    Fontein, D. B. Y.
    Houtsma, D.
    Hille, E. T. M.
    Seynaeve, C.
    Putter, H.
    Kranenbarg, E. Meershoek-Klein
    Guchelaar, H. J.
    Gelderblom, H.
    Dirix, L. Y.
    Paridaens, R.
    Bartlett, J. M. S.
    Nortier, J. W. R.
    van de Velde, C. J. H.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3091 - 3097
  • [44] THE RELATIONSHIP BETWEEN SERUM K+ AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MORTALITY IN UK PATIENTS WITH CKD
    Qin, Lei
    McEwan, Phil
    Evans, Marc
    Bergenheim, Klas
    Horne, Laura
    Grandy, Susan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 73 - 74
  • [45] INCIDENCE OF ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Santos-Moreno, Pedro
    Villarreal-Peralta, Laura
    Cabrera, Michael
    Buitrago-Garcia, Diana
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S91 - S92
  • [46] Oxaliplatin desensitization therapy in patients with colorectal cancer
    Sato, Michiko
    Katsumata, Noriyuki
    ANNALS OF ONCOLOGY, 2023, 34 : S1450 - S1450
  • [47] RELATIONSHIP BETWEEN PARAOXONASE-1 GENOTYPE, ACTIVITY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB
    Charles-Schoeman, C.
    Hyde, C.
    Guan, S.
    Parikh, N.
    Wang, J.
    Shahbazian, A.
    Stockert, L.
    Andrews, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 449 - 450
  • [48] Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
    Charles-Schoeman, Christina
    Hyde, Craig
    Guan, Shunjie
    Parikh, Neil
    Wang, Jennifer
    Shahbazian, Ani
    Stockert, Lori
    Andrews, John
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [49] Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer
    Kumihashi, Yuki
    Kasai, Yohei
    Akagawa, Takuya
    Yuasa, Yasuhiro
    Ishikura, Hisashi
    Sato, Youichi
    JOURNAL OF MEDICAL INVESTIGATION, 2024, 71 (1-2): : 141 - 147
  • [50] Chemotherapy and adverse cardiovascular events in colorectal cancer patients undergoing surgical resection
    Chieh Yang Koo
    Bee-Choo Tai
    Dedrick Kok Hong Chan
    Li Ling Tan
    Ker Kan Tan
    Chi-Hang Lee
    World Journal of Surgical Oncology, 19